Education
About Us
Working with TipRanks
Follow Us
XBiotech (XBIT)
NASDAQ:XBIT
XBIT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.65 - $9.96
Previous CloseN/A
Volume27.99K
Average Volume (3M)48.23K
Market Cap
$96.04M
Enterprise ValueN/A
Total Cash (Recent Filing)-$7.24M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.10
Next EarningsN/A
EPS EstimateN/A
Last Dividend Ex-Date
Jul 15, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding30,487,732
10 Day Avg. Volume53,396
30 Day Avg. Volume48,229
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
XBiotech News
PremiumCompany Announcements
XBiotech Announces Board Member Retirement
PremiumCompany Announcements
XBiotech Appoints Renowned Scientist to Board of Directors
---
Ownership Overview
43.23%
Insiders
5.83% Mutual Funds
0.85% Other Institutional Investors
43.73% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
XBIT FAQ
What was XBiotech’s price range in the past 12 months?
XBiotech lowest stock price was $2.65 and its highest was $9.96 in the past 12 months.
What is XBiotech’s market cap?
XBiotech’s market cap is $96.04M.
When is XBiotech’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were XBiotech’s earnings last quarter?
XBiotech released its earnings results on Mar 14, 2019. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.17.
Is XBiotech overvalued?
According to Wall Street analysts XBiotech’s price is currently Overvalued.
Does XBiotech pay dividends?
XBiotech pays a Notavailable dividend of $2.5 which represents an annual dividend yield of N/A. See more information on XBiotech dividends here
What is XBiotech’s EPS estimate?
XBiotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XBiotech have?
XBiotech has 30,487,732 shares outstanding.
What happened to XBiotech’s price movement after its last earnings report?
XBiotech reported an EPS of -$0.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of XBiotech?
Among the largest hedge funds holding XBiotech’s share is Caxton Associates LP. It holds XBiotech’s shares valued at 0.
---
XBiotech Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.83%
12-Months-Change
Fundamentals
Return on Equity
-19.21%
Trailing 12-Months
Asset Growth
-12.39%
Trailing 12-Months
Company Description
XBiotech
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
---
XBIT Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Galectin Therapeutics
―
Cellectis SA
―
Anixa Biosciences
―
Renovaro Biosciences
―
Vor Biopharma
―
---